Sulforaphane

Name: Sulforaphane
Brand: MedChemExpress
SKU: HY-13755
Rating: 5.0 (53 reviews)

Cat. No.: HY-13755 Purity: 98.87%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties.

For research use only. We do not sell to patients.

Sulforaphane Chemical Structure

CAS No. : 4478-93-7

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 53 publication(s) in Google Scholar

Other Forms of Sulforaphane:

(R)-Sulforaphane Get quote

48 Publications Citing Use of MCE Sulforaphane

: Sulforaphane purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2021 Aug 7;174412. [Abstract]; Immunofluorescence histochemistry confirmes that Sulforaphane (SFN) treatment further increased Nrf2 and HO-1 expression in the dorsal horn of the spinal cord of CIBP rats.

: Sulforaphane purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2021 Aug 7;174412. [Abstract]; Western blotting analysis shows that CIBP can significantly induce the protein expression of Nrf2 and HO-1 in the spinal cord and that intrathecal administration of Sulforaphane (SFN) can further promoted the protein expression of Nrf2 and HO-1 protein.

: Sulforaphane purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jun 5;10(16):7319-7334. [Abstract]; Western blot detection of Nrf2, TLR4, IRF1, iNOS, and ARG-1 levels following Sulforaphane (SFN; 10 μM or 20 μM) treatment or Nrf2 upregulation/downregulation in BMDMs co-cultured with COM-stimulated TECs. SFN treatment activates Nrf2 expression, which then downregulates the expression of TLR4, IRF1, and iNOS and upregulates the expression of ARG-1.

: Sulforaphane purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jun 5;10(16):7319-7334. [Abstract]; The distribution of iNOS (green) and ARG-1 (red) in BMDMs according to immunofluorescence. Sulforaphane (SFN; 10 μM or 20 μM) decreases iNOS and increases ARG-1 levels.

: Sulforaphane purchased from MedChemExpress. Usage Cited in: Vascul Pharmacol. 2018 Oct;109:56-71. [Abstract]; A representative western blot analysis gel showing the reduces abundance of eNOS relative to GAPDH in tissues cultured under hyperglycaemic conditions (25 mM glucose: 25) versus either freshly isolated tissues (F, first lane on left) or tissues cultured under euglycaemic conditions (10 mM glucose: 10). The abundance of eNOS is preserved for tissues cultured in 25 mM glucose along with 1 μM Sulforaphane (25+S).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HDAC Isoform Specific Products:

View All Isoforms

HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

View All Caspase Isoform Specific Products:

View All Isoforms

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

HDAC

Bax

Caspase-3

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	24.52 μM Compound: SFA	Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
A-431	IC₅₀	15.76 μM Compound: SFN	Antiproliferative activity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27135370]
A-431	IC₅₀	9 μM Compound: SFN	Inhibition of EGFR-TK in human A431 cell lysate assessed as reduction in EGF stimulated kinase activity after 60 mins using biotinylated peptide substrate by ELISA Inhibition of EGFR-TK in human A431 cell lysate assessed as reduction in EGF stimulated kinase activity after 60 mins using biotinylated peptide substrate by ELISA	[PMID: 27135370]
A549	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
A549	IC₅₀	11.93 μM Compound: SFA	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
A549	IC₅₀	20.18 μM Compound: SFN	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
A549	IC₅₀	21.99 μM Compound: 77, SFN	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23685571]
AGS	IC₅₀	18.41 μM Compound: SFN	Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
ARPE-19	IC₅₀	10 μM Compound: Sulforaphane	Cytotoxicity against human ARPE-19 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human ARPE-19 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 35549469]
Caco-2	IC₅₀	79.83 μM Compound: SF, Sulforaphane	Cytotoxicity against human Caco2 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human Caco2 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
CCRF-CEM	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human CCRF-CEM cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human CCRF-CEM cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
DU-145	IC₅₀	10 μM Compound: 1	Antiproliferative activity against human DU145 cells assessed as viable cells after 24 hrs Antiproliferative activity against human DU145 cells assessed as viable cells after 24 hrs	[PMID: 18855447]
DU-145	IC₅₀	13.8 μM Compound: SF, Sulforaphane	Cytotoxicity against human DU145 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human DU145 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
HCC827	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human HCC827 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HCC827 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HCT-116	IC₅₀	11.59 μM Compound: 77, SFN	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 23685571]
HCT-116	IC₅₀	36.73 μM Compound: SFA	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
HeLa	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HeLa	IC₅₀	66.09 μM Compound: SFA	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 30282324]
Hep 3B2	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HepG2	EC₅₀	1.2 μM Compound: Sulforaphane	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay	[PMID: 28126440]
HepG2	IC₅₀	14.05 μM Compound: 77, SFN	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23685571]
HepG2	IC₅₀	20.99 μM Compound: SFN	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
HepG2	IC₅₀	24.89 μM Compound: SF, Sulforaphane	Cytotoxicity against human HepG2 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human HepG2 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
HepG2	EC₅₀	4 μM Compound: sulforaphane	Induction of ARE in human HepG2 cells by luciferase assay Induction of ARE in human HepG2 cells by luciferase assay	[PMID: 16562850]
HepG2	IC₅₀	8.357 μM Compound: SFN	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
HONE1 cell line	IC₅₀	19.26 μM Compound: SFN	Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
Jurkat	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
Jurkat	IC₅₀	15 μM Compound: SFN	Cytotoxicity against human Jurkat T cells assessed as decrease in cell viability after 24 hrs by flow cytometric analysis Cytotoxicity against human Jurkat T cells assessed as decrease in cell viability after 24 hrs by flow cytometric analysis	[PMID: 22200402]
Jurkat	IC₅₀	3.8 μM Compound: 1	Antiproliferative activity against human lymphoblastoid cells using annexin-V FITC and PI staining by flow cytometry Antiproliferative activity against human lymphoblastoid cells using annexin-V FITC and PI staining by flow cytometry	[PMID: 18855447]
LoVo	IC₅₀	18.52 μM Compound: SFN	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
LoVo	IC₅₀	22.9 μM Compound: SFN	Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay	[PMID: 29945793]
LoVo	IC₅₀	22.9 μM Compound: SFN	Cytotoxicity against human LoVo cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human LoVo cells after 72 hrs by sulforhodamine B assay	[PMID: 28342398]
MCF7	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
MCF7	IC₅₀	17.66 μM Compound: 77, SFN	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23685571]
MCF7	IC₅₀	23.13 μM Compound: SFN	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
MDA-MB-231	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
MDA-MB-231	IC₅₀	22.18 μM Compound: SFN	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1299	IC₅₀	11.57 μM Compound: SFN	Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1299	IC₅₀	7.648 μM Compound: SFN	Antiproliferative activity against human H1299 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human H1299 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
NCI-H1650	IC₅₀	22.01 μM Compound: SFN	Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1975	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
NCI-H460	IC₅₀	21.25 μM Compound: SFN	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
OVCAR-3	IC₅₀	18.44 μM Compound: SFN	Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
PC-3	IC₅₀	32.38 μM Compound: SF, Sulforaphane	Cytotoxicity against human PC3 cells incubated for 24 hrs by WST1 dye reduction assay Cytotoxicity against human PC3 cells incubated for 24 hrs by WST1 dye reduction assay	[PMID: 22998472]
PC-9	IC₅₀	6.308 μM Compound: SFN	Antiproliferative activity against human PC9 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human PC9 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
Peritoneal macrophage	CC₅₀	> 10 μM Compound: SFN	Cytotoxicity against mouse peritoneal macrophages assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against mouse peritoneal macrophages assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34119834]
RAW264.7	IC₅₀	400 nM Compound: sulforaphane	Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 48 hrs by Griess assay Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 48 hrs by Griess assay	[PMID: 25965897]
SGC-7901	IC₅₀	24.95 μM Compound: SFN	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
SH-SY5Y	IC₅₀	13.27 μM Compound: 77, SFN	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 23685571]
SH-SY5Y	IC₅₀	20 μM Compound: sulforaphane	Cytotoxicity against human SH-SY5Y cells after 24 hrs by Annexin V-PE-based flow cytometry Cytotoxicity against human SH-SY5Y cells after 24 hrs by Annexin V-PE-based flow cytometry	[PMID: 24140951]
SiHa	IC₅₀	9.953 μM Compound: SFN	Antiproliferative activity against human SiHa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human SiHa cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
SMMC-7721	IC₅₀	7.87 μM Compound: SFA	Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK8 assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK8 assay	[PMID: 30282324]
SW480	IC₅₀	17.84 μM Compound: SFN	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
U-251	IC₅₀	22.47 μM Compound: SFN	Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
U2OS	EC₅₀	0.58 μM Compound: SFN	Activation of ED-tagged Nrf2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay Activation of ED-tagged Nrf2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay	[PMID: 31312409]
U2OS	EC₅₀	0.58 μM Compound: SFN	Activation of NRF2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay Activation of NRF2 in human U2OS cells co-expressing Keap1 assessed as induction of NRF2 translocation to nucleus after 6 hrs by beta-galactosidase based chemiluminescent assay	[PMID: 30540174]
U2OS	EC₅₀	0.87 μM Compound: SFN	Activation of NRF2 in human U2OS cells co-expressing Keap1 (unknown origin) assessed as induction of NRF2 translocation to nucleus incubated for 6 hrs by beta-galactosidase based chemiluminescent assay Activation of NRF2 in human U2OS cells co-expressing Keap1 (unknown origin) assessed as induction of NRF2 translocation to nucleus incubated for 6 hrs by beta-galactosidase based chemiluminescent assay	[PMID: 31670201]
U-937	IC₅₀	> 10 μM Compound: SFN	Antiproliferative activity against human U937 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human U937 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 31376566]
Vero	IC₅₀	13.72 μM Compound: 77, SFN	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23685571]

In Vitro

Sulforaphane (0-30 μM) induces cell cycle arrest and apoptosis in a dose-dependent manner. Sulforaphane-induced cell cycle arrest is associated with an increase in the expression of cyclin A and B1^[1].
Sulforaphane (0-30 μM) inhibits the re-initiation of growth and decreases cell viability in HT29 cells, exhibiting lower toxicity towards differentiated cells^[1].
Sulforaphane (10 μM, 24 hours) pre-treatment reduces the number of apoptotic cells, decreases the expression of pro-apoptotic proteins (Bax, caspase-3, cytochrome c), and counteracts the increase in mitochondrial membrane potential induced by Doxorubicin (HY-15142A) (1 μM, 2 hours) in H9c2 cells^[2]. Sulforaphane (10 μM, 2 or 24 hours) effectively reduces ROS production and cell apoptosis in H9c2 cells induced by Doxorubicin (1 μM, 2 or 24 hours) through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	H9c2 cells
Concentration:	Sulforaphane: 10 μM; Doxorubicin: 1 μM
Incubation Time:	Sulforaphane: 2h; Doxorubicin: 2, 24h
Result:	Prevented the release of cytochrome c into the cytosol. Prevented the translocation of Bax into the cytosol. Attenuated the doxorubicin-induced increase in the levels of cleaved caspase-3. Induced a significant increase in HO-1 protein expression. Induced a significantly higher level of Nrf2 expression in the nucleus compared to the cytoplasm.

Apoptosis Analysis^[2]

Cell Line:	H9c2 cells
Concentration:	Sulforaphane: 10 μM; Doxorubicin: 1 μM
Incubation Time:	Sulforaphane: 2h; Doxorubicin: 24h
Result:	Protected the H9c2 cells against doxorubicin-induced cell death. Increased cell viability in a dose-dependent manner. Significantly reduced the number of apoptotic cells treated with Doxorubicin.

RT-PCR^[2]

Cell Line:	H9c2 cells
Concentration:	Sulforaphane: 10 μM; Doxorubicin: 1 μM
Incubation Time:	Sulforaphane: 2, 24h; Doxorubicin: 2, 24h
Result:	Induced heme oxygenase-1 (HO-1) mRNA expression in a dose-dependent manner.

In Vivo

Sulforaphane (13.3, 17.7, 26.6 mg/kg; Oral gavage; 5 days) is capable of inhibiting the formation of mammary tumors in female Sprague-Dawley rats following a single-dose treatment with DMBA (HY-W011845) (8 mg/mL)^[3].
Sulforaphane (13.3, 17.7, 26.6 mg/kg; Oral gavage; 5 days) can reduce the incidence, multiplicity, and weight of mammary tumors induced by DMBA (8 mg/mL) in female Sprague-Dawley rats, and delay their development^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Sprague-Dawley rat^[3]
Dosage:	Sulforaphane: 13.3, 17.7, 26.6 mg/kg; DMBA (HY-W011845): 8 mg/mL
Administration:	Oral gavage; 5 days
Result:	Prevented the occurrence of tumors in a dose-dependent manner. Significantly reduced the incidence of tumors.

Clinical Trial

Molecular Weight

177.29

Formula

C₆H₁₁NOS₂

CAS No.

4478-93-7

Appearance

Liquid (Density: 1.17±0.1 g/cm³)

Color

Colorless to light yellow

SMILES

O=S(CCCCN=C=S)C

Structure Classification

Others

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture and light

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility

In Vitro:

DMSO : ≥ 62.5 mg/mL (352.53 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.6405 mL	28.2024 mL	56.4048 mL
5 mM	1.1281 mL	5.6405 mL	11.2810 mL
10 mM	0.5640 mL	2.8202 mL	5.6405 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (14.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: ≥ 50 mg/mL (282.02 mM); Clear solution
Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: ≥ 50 mg/mL (282.02 mM); Clear solution
Protocol 3

Add each solvent one by one: 30% SBE-β-CD in Saline
Solubility: 10 mg/mL (56.40 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.75%

Select Batch:

Data Sheet (277 KB) SDS (421 KB)

COA (242 KB) HNMR (191 KB) LCMS (139 KB)

Handling Instructions (2659 KB)

References

[1]. Gamet-Payrastre L, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000 Mar 1;60(5):1426-33. [Content Brief]

[2]. Li B, et al. Sulforaphane prevents doxorubicin-induced oxidative stress and cell death in rat H9c2 cells. Int J Mol Med. 2015 Jul;36(1):53-64. [Content Brief]

[3]. Zhang Y, et al. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornylisothiocyanates. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3147-50. [Content Brief]

[4]. Chen X, et al. Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of PancreaticCancer via AMPK Dependent Signaling. ell Physiol Biochem. 2018;50(3):1201-1215. [Content Brief]

[5]. De Nicola GR, et al. Novel gram-scale production of enantiopure R-sulforaphane from Tuscan black kale seeds. Molecules. 2014 May 27;19(6):6975-86. [Content Brief]

[6]. Abdull Razis AF, et al. The natural chemopreventive phytochemical R-sulforaphane is a far more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer. Int J Cancer. 2011 Jun 15;128(12):2775-82. [Content Brief]

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.6405 mL	28.2024 mL	56.4048 mL	141.0119 mL
	5 mM	1.1281 mL	5.6405 mL	11.2810 mL	28.2024 mL
	10 mM	0.5640 mL	2.8202 mL	5.6405 mL	14.1012 mL
	15 mM	0.3760 mL	1.8802 mL	3.7603 mL	9.4008 mL
	20 mM	0.2820 mL	1.4101 mL	2.8202 mL	7.0506 mL
	25 mM	0.2256 mL	1.1281 mL	2.2562 mL	5.6405 mL
	30 mM	0.1880 mL	0.9401 mL	1.8802 mL	4.7004 mL
	40 mM	0.1410 mL	0.7051 mL	1.4101 mL	3.5253 mL
	50 mM	0.1128 mL	0.5640 mL	1.1281 mL	2.8202 mL
	60 mM	0.0940 mL	0.4700 mL	0.9401 mL	2.3502 mL
	80 mM	0.0705 mL	0.3525 mL	0.7051 mL	1.7626 mL
	100 mM	0.0564 mL	0.2820 mL	0.5640 mL	1.4101 mL

Sulforaphane Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sulforaphane4478-93-7HDACKeap1-Nrf2ApoptosisBcl-2 FamilyCaspaseReactive Oxygen SpeciesHistone deacetylasesBaxCaspase-3Cytochrome cHT29DoxorubicinMitochondrial membrane potentialInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Sulforaphane

Customer Review

Other Forms of Sulforaphane:

Sulforaphane Related Antibodies

48 Publications Citing Use of MCE Sulforaphane

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HDAC Isoform Specific Products:

View All Bcl-2 Family Isoform Specific Products:

View All Caspase Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Sulforaphane Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Sulforaphane Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report